Avid Bioservices Inc (CDMO)

[entdoc]

for those doing DD here (lord help you sort through it all), PPHM has patents on not only a new and different type of anti-cancer monoclonal antibody, Bavituximab, but on an entirely new PLATFORM of potential new treatments for a wide array of inflammatory and neoplastic diseases. The platform is based on the fact that oxidatively stressed cells "flip" inside-out a group of compounds which are components of their cell membranes---phospholipids--- and these flipped phospholipids (example: phosphatidylserine [e.g.,-PS], become an exclusive docking site for attack by PPHM monoclonal antibody {"MAB"} constructs such as Bavituximab. The preclinical work and human trials with Bavituximab have been extensive, and positive. Recent preclinical trial results with Bavituximab combined with irradiation have been very positive. Bavituximab, combined with standard chemotherapy, is in Phase III clinical trials in humans for treatment of advanced lung cancer.